Between January and May 2018, Russia imported 198.7 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms 2% higher than that of the same period of 2017, and 42.7 bln RUB worth of in-bulk pharmaceutical drugs, which is in monetary terms 20.3% higher than that of the same period of 2017. The total dynamics are 4.8%.

In May 2018, Russia imported 42.6 bln RUB worth of ready-made drugs (free circulation prices), which is in monetary terms 6% higher than that of May 2017. Against 18% in February, the dynamics leave much to be desired. The import volume of in-bulk drugs is 6.8 bln RUB, which is 8% lower than that of May 2017.

In physical terms, Russia imported 726.4 mln units of ready-made drugs between January and May 2018, which is 8% lower than that of the same period of 2017. The import volume of in-bulk drugs amounted 1.8 bln minimum dosage units (MDU) over the period, which is 1.5% lower than that of the same period of 2017. The total import volume is 15.5 bln MDU, which is 4.6% lower than that of the same period of 2017.

Roche (Switzerland) is one of the leaders in the import of ready-made drugs. Its import has more than doubled, with anti-tumor drug Erivedge having contributed considerably to the dynamics (its import has increased by nearly 28 times). Celgene is one of the leaders in the import of in-bull drugs, with a 15.5 times increase. Revlimid, which is packaged in Kursk (Farmstandart-Leksredstva) has contributed a lot to the dynamics.

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – May 2018)